• AIM: To report long-term outcomes of secondary glaucoma due to uveitis treated with Ahmed glaucoma valve (AGV) implantation in a series of Chinese patients.
INTRODUCTION

G
laucoma is a leading cause of blindness disease and is characterized by elevated intraocular pressure (IOP), optic nerve damage and visual defects [1] . Some types of glaucoma include neovascular glaucoma, secondary glaucoma associated with uveitis, and angle recession, which usually are bad responsive to conventional medical therapies and surgical procedures [2] [3] . Uveitis is swelling and irritation of the uvea which is the middle layer of the eye. It accounts for 5%-20% of blindness cases in the United States and Europe [4] . One of the major complications is glaucoma which arises secondary to uveitis or the corticosteroids used to treat uveitis [1, [5] [6] . Uveitic glaucoma is difficult to manage because it may be difficult to obtain a desirable IOP through medical treatments and surgeries. There are many therapies used to treat of uveitic glaucoma. One of the most common procedures used is trabeculectomy. The major complication of this procedure is bleb fibrosis [7] [8] .
Although the application of anti-fibrotic agents such as mitomycin C, have been used in surgery, the success rate of filtration surgery remains unsatisfactory [9] . Furthermore, as the recurrent inflammatory response of uveitis transpires in these patients, filtration surgery in uveitic glaucoma yields lower success rates than other refractory glaucoma [10] . In recent years, aqueous drainage devices have been widely used to treat uveitic glaucoma. The Ahmed glaucoma valve (AGV) is a shunt device used to restrict flow in uveitic glaucoma [11] [12] . It has shown better surgical results with fewer postoperative complications compared with traditional surgical procedures in uveitic glaucoma [12] . The success rates of AGV implantation are higher in some studies compared with trabeculectomy [12] [13] [14] . However, success rates are inconsistent among different studies. Moreover, there is little report of success rates of AGV in Chinese uveitic glaucoma. Herein, we present the outcomes of patients with uveitic glaucoma who were treated with AGV implantation.
SUBJECTS AND METHODS Study Population
This was a retrospective and non-comparative study of AGV implantation. We reviewed the records of all uveitic glaucoma patients who underwent AGV implant surgery at the Department of Ophthalmology, the Second Affiliated Hospital of Anhui Medical University from Jun. 2009 to Apr. 2012 due to glaucoma that was uncontrolled by medical treatment or with glaucoma surgery. This study contained 67 eyes of 56 patients with uveitic glaucoma. Clinical information including age, gender, race, number of anti-glaucoma medications, previous glaucoma surgeries were collected. As active uveitis may influence the outcome of surgery, the patients in the study were clinically in remission for over 6mo and received oral prednisone 1 mg/kg·d and were tapered for 3wk [1, 15] . All the patients underwent a full ophthalmic examination, including visual acuity (VA), IOP, slit-lamp examination of the anterior chamber, gonioscopy, central corneal thickness, measurement of IOP, fundus examination with special attention to optic disc parameters, retinal nerve fiber layer (RNFL), and visual field (VF). The study was approved by the Local Institutional Ethnics Committee of the Second Affiliated Hospital of Anhui Medical University and met the tenets of the Declaration of Helsinki. The participants provided their written consent to participate in this study. Surgical Technique All AGV implant surgeries were performed under retrobulbar anesthesia by the same surgeon, with the use of a fornix-based conjunctival and Tenon's capsule flap. The surgery involved a standard technique which was mentioned in the previous studies. Firstly, in order to expose a surgical field, the corneal traction suture was anchored at the peripheral cornea using 8-0 nylon. An AGV single-plate silicone implant (New World Medical Inc., Rancho Cucamonga, CA, USA) was used in all patients. Secondly, a conjunctiva and Tenon's capsule incision of approximately 10 mm were made circumferentially at 5 mm posterior from the limbus in the supratemporal quadrant, and the sub-Tenon's space was undermined. The implant was primed by the injection of saline solution through a 25-gauge blunt cannel. The body of the implant was secured onto the sclera at 8 to 10 mm posterior from the limbus with a 10-0 nylon suture. Paracentesis into the anterior chamber was made with a 23-gauge needle at 2 mm posterior to the limbus. A paracentesis was performed temporally for the injection of viscoelastic material. Next, a silicone tube was cut, and a length of approximately 2 mm was inserted into the anterior chamber through this needle track, which was secured to the sclera with three 10-0 nylon sutures. A full thickness donor scleral patch graft, 4 mm×3 mm in size, was attached over the tube near the limbus and secured. The conjunctiva was then closed with 10-0 nylon sutures. preoperative and postoperative VA were summarized in Table 2 . The VF and RNFL were stable during the following time.
Management After Surgery
Number of Medications The number medications used was significantly decreased in postoperative glaucoma patients. Table 2 showed the number medications in patients before and after operation. The average number of glaucoma medications decreased from 3.1±0.6 medications at baseline to 0.5±0.3 at 1mo, 0.9±0.4 at 3mo, 0.9±0.2 at 6mo, 1.2±0.5 at 12mo, 1.3±0.4 at 24mo, 1.1±0.3 at 36mo and 1.2±0.5 at 60mo.
Additional Surgeries and Surgical Complications
In the study, 14 of the 67 eyes underwent AGV implantation in combination with other intraocular surgery including phacoemulsification (n=9), pars plana vitrectomy (n=2), anterior vitrectomy (n=3). The major intraoperative complications of AGV implantation in this group was hyphema (3 of 67 eyes, 4.5%) and no other complications occurred during the surgery. There were some complications after the AGV implantation. In present study, on one hand, the most common early postoperative complication (<3mo) was transient hypotony which was defined as IOP<5 mm Hg and was observed in 12 eyes. Shallow anterior chambers were found in 7 eyes in the early postoperative period. Totally 6 eyes had moderate hyphema and the AGV tube of one eye was obstructed, 10 eyes had corneal edema. No other corneal complication and would leak were found in the patients. On the other hand, the postoperative complications (>3mo) were found in the study that included tube occlusion, bleb fibrosis, retinal detachment and recurrent uveitis. Totally 5 eyes had tube occlusion at 60mo, the bleb fibrosis was found in 15 eyes at 60mo after surgery, 6 eyes had recurrent uveitis (ankylosing spondylitis in 4 eyes, Vogt-Kayanga-Harada syndrome in 2 eyes) which caused the fail of AGV implantation in uveitic patients. Retinal detachment was found in 2 eyes at 12mo after surgery. The results were shown in Table 3 . DISCUSSION Uveitis is a common cause of blindness and is characterized by recurrent intraocular inflammation of the eyes. The recurrent uveitis leads many inflamed cells to obstruct the trabeculum, and thus the aqueous humor is unable to flow through the trabeculum. These results led to many types of complications; glaucoma is one of them [1] . Uveitic glaucoma is difficult to manage because of its therapeutic challenges and the lifetime burden of vision loss if the disease is not treated [1, 16] . Although glaucoma surgeries have a relatively low success rate in treating uveitic glaucoma, they are thought to be useful methods of controlling IOP. Various studies have reported that glaucoma drainage devices are more effective methods of reducing IOP in uveitic glaucoma than other conventional treatments [17] [18] [19] . As a glaucoma drainage device, the AGV is a shunt device with a restriction flow mechanism that is used in uveitic glaucoma and the study revealed that the complication rate of AGV implants is lower than other kinds of valves [15, 19] . The success rate of AGV implantation is very important to evaluate the effect of AGV implantation. In past years, the success rates of AGV varied in uveitic glaucoma patients among different populations [12, 14, 17, 19] . The success rates of this study were 83.6% at 12mo after surgery, 70.1% at 36mo after surgery, and 61.2% at 60mo after surgery. The success rates of drainage implantation in uveitic glaucoma were different in these studies. On one hand, the success rates of some studies about uveitic glaucoma were higher than that of this study. Satana et al [17] reported that AGV implantation in the 14 eyes of 10 patients with uveitic glaucoma secondary to Behcet's disease and success rates (i.e. IOP between 6 and 21 mm Hg) of 90.9% after 18mo and 72.7% after 24mo. The recent study reported that AGV implantation in 24 eyes with uveitic glaucoma had a success rate of 100% at 12mo after surgery [12] . On the other hand, a few studies had lower success rate when compared with our study. A retrospective study of 60 eyes of 60 uveitic glaucoma patients who underwent AGV implantation revealed that success rates (IOP range 5 to 21 mm Hg and a 25.0% decrease in IOP from before surgery) of 77.0% after 1y surgery and 50.0% after 4y surgery [20] . The results were different among them because the definitions used to define success varied and the severity of uveitic glaucoma was diverse. Firstly, the definition of success in this study combined both the IOP between 5 and 21 mm Hg and a 20.0% decrease in IOP from that before surgery. This definition is stricter than that of higher success rate studies. Secondly, the conditions of patients in our study were extremely diverse that 86.6% patients had undergone previous ocular surgery and 38.8% had prior glaucoma surgery. These two reasons may explain the differing success rates between the AGV implantation studies. In order to improve the success rate of AGV surgery, we made sure that the patients were not in a period of active uveitis and that they received prednisone treatment before and after surgery [1, [21] [22] . The postoperative VA was similar to preoperative VA. The VF and RNFL were stable after the surgery. The IOP and number of anti-glaucoma medications were significantly decreased in postoperative patients. These results suggested that AGV implantation was effective in controlling IOP and reducing medication use without VA, VF and RNFL loss. Like many other studies concerning AGV implantation, this study had many complications. There were several postoperative complications (<3mo) in the present study. In previous studies, the transient hypotony, hyphema, leaking, and corneal complications were common in the early periods after surgery [23] [24] . Transient hypotony, hyphema and shallow anterior chambers were usually happened in during operation and the early postoperative period. The results were explained by the lower ocular pressure and pancreatic the 25-gauge blunt cannel during the surgery. The incidences of transient hypotony and shallow anterior chambers may be reduced through injections of viscoelastic materials into the anterior chamber at the end of AGV surgery. The AGV tube was blocked by hyphema in 1 eye, which caused high pressure. Totally 10 eyes had corneal edema with no other corneal complications. This finding was not consistent with the results by others [17, 25] . Some studies reported corneal complications as the most common and serious in their studies because some patients had corneal grafts. However, no patient in our study had corneal implantations and this may be an important reason for low corneal complications. The postoperative complications (>3mo) may have influenced the success rate. Tube occlusion and bleb fibrosis were major factors which led to shunt failure of AGV implantation [7] . The bleb fibrosis was resulted in 15 patients having shunt failure after 5y surgery. The postoperative fibrotic capsule that forms around the AGV was the primary resistance to aqueous outflow and was considered as a crucial risk factor for failure of AGV surgery [4, 26] . Many studies revealed that antifibrotic agent was a detriment to trabeculectomy survival [12, [27] [28] . However, recent study showed that the use of mitomycin C was not related the success rate of AGV implantation [20] . Interestingly, mitomycin C-induced tissue damage was reported to induce a reactive fibrosis adjacent to the area around the AGV, which resists aqueous flow through the shunt [29] . Based on the above reasoning, we did not use mitomycin C during the surgeries for the patients with uveitis in the present. As the patients in present study were all Chinese and diagnosed with uveitic glaucoma, they were clinically in remission for over 6mo and received oral prednisone before the operation, the complications of the study were relative low. The current study had the limitations of a retrospective design, a small size of patients and the relative short duration of followup. Collected data were limited to how corneal endothelial cells changed in study. These may limit the evaluation of the severity of uveitic glaucoma. Another limitation is that the patients who did not follow-up were not included. In conclusion, the present study revealed the outcomes of AGV implantation in Chinese uveitic glaucoma. Our results demonstrated that AGV implantation is effective and safe for patients with uveitic glaucoma. Corneal edema and hypotony were two common early postoperative complications. In addition, bleb fibrosis was another postoperative complication in AGV surgery in Chinese uveitic glaucoma.
